Lipid metabolism and renal disease

Area of Science:

• Nephrology
• Metabolic Diseases
• Cardiovascular Health

Background:

• Metabolic syndrome is linked to dyslipidemia, a potential driver of chronic kidney disease (CKD).
• Lipid metabolism dysregulation in CKD mirrors metabolic syndrome, accelerating disease and increasing cardiovascular mortality.
• Understanding these lipid alterations is crucial for managing CKD patients.

Purpose of the Study:

• To review factors regulating intracellular lipid handling in relation to mesangial cell function.
• To highlight key factors altered in metabolic syndrome and their role in CKD.
• To emphasize lipid-induced kidney damage, including foam cell formation and fibrosis.

Main Methods:

• Literature review focusing on intracellular lipid handling mechanisms.
• Analysis of factors altered in metabolic syndrome (e.g., fatty acid translocase, PPAR-delta, IGF-1, inflammation, hypertriglyceridemia).
• Examination of lipid-mediated changes in kidney cells and their pathological outcomes.

Main Results:

• Metabolic syndrome-associated factors disrupt lipid metabolism and mesangial cell function.
• CKD exacerbates lipid abnormalities, including increased triglycerides and decreased HDL.
• Lipid accumulation in kidney cells promotes glomerulosclerosis and interstitial fibrosis, with foam cells playing a key role.

Conclusions:

• Dysregulated lipid handling is a critical link between metabolic syndrome and CKD.
• Targeting lipid metabolism pathways may offer therapeutic strategies for CKD.
• These lipid changes significantly increase cardiovascular risk in CKD patients.